Caffeine is a stimulant thought to activate the pleasure centre in the brain, commonly used in the general public for purposeful attempt to alter mood, and also commonly perceived to be a bladder irritant with associated urgency and frequency symptoms. Mental health diagnosis, such as depression, is also associated with overactive bladder. Taken together, it is plausible that women with overactive bladder symptoms along with comorbid mental health symptoms may also show higher caffeine intake but no data exist. This pilot study's purpose was to determine in women with overactive bladder, if those with a mental health diagnosis (we included anxiety, depression, post-traumatic stress disorder and bipolar diagnosis) consume a significantly higher amount of caffeine than those without any of these diagnoses. Secondary analysis was performed on data from women with overactive bladder recruited into a longitudinal parent study on beverage management. All parent study participants met criteria of urgency and voiding more than seven times per day. Each kept a detailed 3-day diary of beverage intake. From the total parent study pool of 61, we identified 14 women with a comorbid mental health diagnosis as described above and 47 without when interviewed at baseline. Women with mental health diagnosis demonstrated higher median baseline caffeine intake per day than their counterparts without mental health diagnosis: 240·2 mg (range: 72·3-576·0 mg) versus 174·3 mg (range: 0-567·6 mg), which was marginally significant (p = ·053). Volume of caffeinated beverage intake did not differ significantly. In women with overactive bladder and comorbid mental health symptoms, higher caffeine intake may be a previously unrecognized link. Cause and effect is unknown between the three conditions of overactive bladder, mental health disorders and higher caffeine intake; but this initial data support the need for further research.
BACKGROUND
It is a common practice among health care providers to relate overactive bladder (OAB) symptoms to excess consumption of caffeine. A typical first-line treatment for women presenting to their health care providers with OAB is to decrease or eliminate caffeinated beverages. Although data linking caffeine to OAB symptoms are sparse, there is an abundance of expert advice to decrease or eliminate caffeine, for instance as published on well-respected websites: 'National Association for Continence ' (NAFC, 2008) ; 'Cleveland (NICE, 2006) .
Data show that higher rates of bladder disorders (voiding frequency, urgency and incontinence) are linked with mental health conditions (Zorn et al., 1999; Weissman et al., 2000; Nygaard et al., 2003; Melville et al., 2005; Moghaddas et al., 2005; Fitzgerald et al., 2007; Link et al., 2007) , though the underlying mechanism involved is not understood. Causal factors suggested include some alteration stemming from sexual abuse , a candidate gene (Weissman et al., 2000) , and noradrenaline and serotonin dysregulation (DeGroat, 2002) . None of these explanations completely explain the linkage between bladder disorders and mental health conditions. A tenable companion hypothesis is that OAB and mental health diagnoses are linked in part by caffeine, one of the world's most popular mood-altering drugs. Caffeine is known to activate the pleasure centre in the brain (Kelly and Mac Evilly, 2001; Lorist and Tops, 2003) . Thus, it is reasonable to assume that caffeine, a readily available and socially accepted drug, could be used as a form of self-medication for those experiencing mood disorders. If so, and if caffeine is also a bladder irritant, then women with a mental health diagnosis may inadvertently trigger or exacerbate symptoms of OAB, symptoms which might otherwise not exist at clinically significant levels.
RESEARCH QUESTION
To begin to explore this possible connection, we performed a small pilot study using data available from a longitudinal parent study on beverage management as treatment for OAB. Using only the baseline data from the parent study, we tested the hypothesis that women with comorbid OAB and mental health diagnoses would demonstrate higher caffeine intake on 3-day diaries than those with OAB alone.
SAMPLE
The parent study (analysis of longitudinal data is ongoing) recruited 61 community-dwelling women through newspaper advertising after obtaining Institutional Review Board (IRB) approval. Inclusion criteria included: female, age 18 and older, greater than seven voids per day or two per night, daily consumption of at least 16 ounces of beverages potentially irritating to the bladder (coffee, tea, alcohol or caffeinated beverages), greater than 32 ounces of overall beverage intake per day, and an answer of 'yes' to the question, 'Do you experience frequent, strong feelings of urgency to empty your bladder?' Exclusion criteria included women who were pregnant, had diabetes, were taking diuretic pills, and women who experienced pain when urinating or had frequent urinary tract infections. In addition, women who had surgery for incontinence within the past year could not participate because of the likelihood of the surgical procedure causing the symptoms of OAB. Cognitively impaired adults were excluded because of the difficulty in diary keeping and consistency in educational delivery. Informed consent was obtained and participants enrolled.
The study design for this secondary analysis of baseline data was retroactive case control. We retrospectively assigned women as 'cases' if baseline data from the parent longitudinal study included a diagnosis of one of the following mental health diagnoses: anxiety, depression, post-traumatic stress disorder or bipolar disorder (23%, n = 14), or if medications indicated the same. Those women from the parent study without a mental health diagnosis served as controls (77%, n = 47).
DATA COLLECTION METHODS
Upon entry into the longitudinal parent study, women were given a DVD as well as written instructions on how to keep a detailed 3-day diary at home and were instructed to be as specific as possible. They were given precise examples on how to record beverage intake on their diary (e.g. Starbucks caffeinated coffee, grande 16 ounces). Food intake was not recorded, so only data on caffeine consumed through beverages were available for analysis. The diary form used was designed for the parent study and is appended (Appendix A). The parent intervention study requires data on both intake and bladder and bowel output, as well as symptom change measured by OAB questionnaires (Bower et al., 2001; Coyne et al., 2002; de Wachter, 2003) . Although women from the parent study completed three 3-day diaries, only the intake data from the baseline diary were utilized for analysis in this report.
A nurse practitioner gathered additional information in a clinical setting through an interview and questionnaires, including information about each subject's past and current medical diagnoses, medications, and demographics; height and weight were measured. Participants were assigned identification numbers to preserve anonymity.
DATA ANALYSIS
The secondary analysis represented here was conducted as pilot information to determine worthiness of future investigation on the potential linkage between caffeine, mental health conditions and OAB.
Data management of the baseline 3-day intake portion of the participants' diaries for this analysis was conducted as follows. Caffeine was quantified in milligrams using a variety of sources to obtain precise content calculations. Primarily, we relied on USDA data and specific brand websites (Coca-Cola, Pepsi, Folgers, etc.) . Details of caffeine conversions by product are appended (Appendix B). Three-day tallies of caffeine intake in milligrams, caffeinated beverage intake in ounces and total beverage intake in ounces were all reduced to daily averages. Descriptive analysis was used to characterize the sample and graphical portrayal of the data provided additional information. Scatter-plots were used to examine data on age or body mass index (BMI) in relation to caffeine intake.
For hypothesis testing, distribution free statistics were used when data were not normally distributed.
The non-parametric Mann-Whitney U test was used to test for differences in caffeine intake, measured in milligrams, between women with and without a mental health diagnosis and an independent t-test was used to determine whether volume of caffeinated beverage intake, measured in ounces, differed between groups. A p-value of ·05 was used to determine significance. A priori power analysis was not conducted as we relied on the fixed sample size of the parent study that was primarily designed for longitudinal analysis.
RESULTS
The women were on average 48 years old, ranging from 20 to 88 years, and 87% were Caucasian, 59% had at least one vaginal delivery and 65% had a college education. All women met OAB criteria of voiding greater than seven times per day and/or greater than two times per night and said 'yes' on entrance screening to the question 'Do you experience frequent, strong feelings of urgency to empty your bladder?' The daily average of milligrams of caffeine intake was 205·1 mg (standard deviation = 140·8). Amount of caffeine intake in relation to age and BMI are portrayed graphically in Figures 1 and 2 .
To display the data according to cases and controls, Figure 3 shows box plots of caffeine intake Figure 1 The scatter-plot shows that caffeine intake and age do not appear to correlate in this sample.
Figure 2
The scatter-plot shows that caffeine intake and body mass index (BMI) do not appear to correlate in this sample.
in milligrams. The median (range) of caffeine intake for cases was 240·2 (72·3-576·0) mg per day, whereas for controls it was 174·3 (0-567·6) mg per day: a marginally significant difference in this small sample size (U = 216, z = −1·9, p = ·053). Volume of caffeinated beverage intake (mean ± SD ounces) did not differ statistically between those with and without a mental health diagnosis (77·1 ± 20·7 versus 70·4 ± 24·3 ounces, respectively, p = ·36), but the trend towards higher volume in the group with a mental health diagnosis suggests this may be a limitation of our sample size.
DISCUSSION
This study showed that women with a diagnosis of depression, anxiety, post-traumatic stress disorder or bipolar disorder and who have concomitant OAB may have a disproportionate intake of caffeine (approximately 33% more in this study) when compared to women with similar OAB symptoms but without a mental health diagnosis. The women with a mental health diagnosis studied here, preferentially selected more highly caffeinated drinks as their beverage of choice, perhaps to positively affect mood.
Results of this small pilot work should be interpreted with caution, but this initial investigation provides beginning support for our working hypothesis that caffeine, mental health conditions and OAB may be linked. To our knowledge, this is the first time that this link has been addressed with data. This may be because collecting data at the level of precision needed is difficult and burdensome. This study, despite being small and a secondary analysis, had the advantage of quantifying caffeine intake with far greater detail than usually obtained on standard voiding diaries, thus allowing more exact calculation of caffeine consumption. Even with this higher precision, caffeine sources from food, for instance a chocolate bar, were not included, so the estimate of actual caffeine intake may still be low.
We reiterate that the parent study was not fully powered to address this secondary research question, and the data should be considered pilot with limited generalizability until findings are confirmed by additional research. In addition, study groups may not have been pure; for instance, those placed in the control group may have actually had a mental health problem, but had not sought help from a health care provider, and as such did not have a formal diagnosis. We also did not extensively investigate the relationship between medications taken by the women with mental health diagnoses, which may have differed from those without diagnoses, and could possibly have Figure 3 Boxplots showing 3-day average of caffeine intake in milligrams by cases (subjects who had a mental health diagnosis) and controls.
influenced beverage intake, for instance in response to side-effects, such as dry mouth. However, there were no significant differences observed between the volumes of total beverage intake in the two study groups, suggesting volume increase alone was not the contributing factor for OAB in women with mental health diagnoses. Our study also did not describe the caffeine intake profile before the onset of symptoms of either depression or OAB and the retrospective design does not allow determination of cause and effect.
CONCLUSION
Although replication of the findings is warranted, this initial pilot work provides the first data, to our knowledge, that caffeine intake may by higher in women with mental health conditions and might inadvertently produce or exacerbate symptoms of OAB.
